Literature DB >> 33585700

An artificial immune system with bootstrap sampling for the diagnosis of recurrent endometrial cancers.

Chih-Yen Chang1,2, Yen-Chiao Angel Lu3, Wen-Chien Ting4, Tsu-Wang David Shen5,6, Wen-Chen Peng7.   

Abstract

Endometrial cancer is one of the most common gynecological malignancies in developed countries. The prevention of the recurrence of endometrial cancer has always been a clinical challenge. Endometrial cancer is asymptomatic in the early stage, and there remains a lack of time-series correlation patterns of clinical pathway transfer, recurrence, and treatment. In this study, the artificial immune system (AIS) combined with bootstrap sampling was compared with other machine learning techniques, which included both supervised and unsupervised learning categories. The back propagation neural network, support vector machine (SVM) with a radial basis function kernel, fuzzy c-means, and ant k-means were compared with the proposed method to verify the sensitivity and specificity of the datasets, and the important factors of recurrent endometrial cancer were predicted. In the unsupervised learning algorithms, the AIS algorithm had the highest accuracy (83.35%), sensitivity (77.35%), and specificity (92.31%); in supervised learning algorithms, the SVM algorithm had the highest accuracy (97.51%), sensitivity (95.02%), and specificity (99.29%). The results of our study showed that histology and chemotherapy are important factors affecting the prediction of recurrence. Finally, behavior code and radiotherapy for recurrent endometrial cancer are important factors for future adjuvant treatment.
© 2021 Chih-Yen Chang et al., published by De Gruyter.

Entities:  

Keywords:  artificial immune systems; biomimetic intelligence; bootstrap sampling; recurrent endometrial cancers

Year:  2021        PMID: 33585700      PMCID: PMC7863001          DOI: 10.1515/med-2021-0226

Source DB:  PubMed          Journal:  Open Med (Wars)


  15 in total

1.  Radiation therapy for endometrial cancer in patients treated for postoperative recurrence.

Authors:  K B Hart; I Han; F Shamsa; W S Court; P Chuba; G Deppe; J Malone; C Christensen; A T Porter
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-04-01       Impact factor: 7.038

Review 2.  Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.

Authors:  Christine M Bestvina; Gini F Fleming
Journal:  Oncologist       Date:  2016-07-13

3.  Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.

Authors:  Jerlinda G C Ross; Veronica Escamilla; Nita Karnik Lee; S Diane Yamada; Stacy Tessler Lindau
Journal:  Gynecol Oncol       Date:  2018-12-20       Impact factor: 5.482

4.  Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis.

Authors:  Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen
Journal:  JAMA Intern Med       Date:  2018-09-01       Impact factor: 21.873

5.  Essential roles of mesenchyme-derived beta-catenin in mouse Müllerian duct morphogenesis.

Authors:  Erica Deutscher; Humphrey Hung-Chang Yao
Journal:  Dev Biol       Date:  2007-05-03       Impact factor: 3.582

6.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

7.  Factors predicting recurrent endometrial cancer.

Authors:  A N J Huijgens; H J M M Mertens
Journal:  Facts Views Vis Obgyn       Date:  2013

Review 8.  Therapeutic management options for stage III non-small cell lung cancer.

Authors:  Stephanie M Yoon; Talha Shaikh; Mark Hallman
Journal:  World J Clin Oncol       Date:  2017-02-10

Review 9.  Clinical actionability of molecular targets in endometrial cancer.

Authors:  Mary Ellen Urick; Daphne W Bell
Journal:  Nat Rev Cancer       Date:  2019-08-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.